

CE ISO 13485 : 2016

## **AMKAY PRODUCTS LIMITED**

## Mfg.of Medical Devices & Disposables

Regd. Office: Amkay Enclave, 68, Rashmi Park Bungalow, Dhumaal Nagar, Waliv Road, Vasai (East), Palghar - 401208, Maharashtra, India.

Email: info@amkayproducts.com Website: www.amkayproducts.com

Phone: 91520 94440 CIN: U51397MH2007PLC175403

Date: 12th November, 2025

To, The Manager Compliance Department BSE Limited P.J. Towers, Dalal Street, Fort Mumbai-400001

Scrip Code: 544169

#### Sub.: Outcome of Board Meeting held on Wednesday, 12th November, 2025

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and other applicable provisions, if any, We would like to inform you that the meeting of the Board of Directors of Amkay Products Limited held today i.e. Wednesday, 12<sup>th</sup> November, 2025 through VC/OAVM inter-alia has considered and approved the following businesses:

1. Unaudited financial results for the half year ended September 30, 2025 of the company along with Limited Review Report are enclosed herewith for information and record;

Please note that in terms of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company will open after 48 hours of the results are made public on Wednesday, 12<sup>th</sup> November, 2025.

Also please note that the Board meeting commenced at 4.30 p.m. to conclude at 05.25 p.m.

Kindly take the same on your record.

Thanking You

Yours Faithfully
For Amkay Products 1

For Amkay Products Limited

Kashyap Pravin Mody Managing Director DIN: 01717036



## Amkay Products Limited (Formerly Known as Amkay Products Private Limited)

Registered Office -: Bunglow No.68,Rashmi Park Chs Ltd, Dhumal Nagar Waliv Road, Tal-Vasai Dist- Thane Vasai Thane Maharashtra - 401208, CIN - : L51397MH2007PLC175403

Profit & Loss Statement For The Half Year Ended September 30th, 2025

(Rs In Lakhs)

Sr.	Particulars	На	olf Year Ended		
No.		30-Sep-25	31-Mar-25	30-Sep-24	31-Mar-25
	Whether Results are Audited or Unaudited	Unaudited	Audited	Unaudited	Audited
1	Revenue From Operations	2301.14	2055.19	1783.82	3839.01
П	Other Income	39.31	59.32	72.51	131.83
Ш	Total Revenue (I+II)	2340.45	2114.50	1856.33	3970.84
IV	Expenses:				
а	Cost Of Material Consumed	560.56	1184.17	807.61	1991.78
b	Purchase Of Stock-In-Trade Changes In Inventories Of Finished Goods, Work-In-Progress And Stock -	958.30	554.47	371.87	926.34
C	In-Trade	16.88	-299.60	5.79	-293.81
d	Employee Benefits Expenses	163.50	159.52	137.50	297.02
е	Finance Costs	25.38	13.83	17.83	31.66
f	Depreciation And Amortization Expense	42.63	48.92	34.03	82.95
g	Other Expenses	304.40	283.59	221.55	505.13
	Total Expenses	2071.65	1944.90	1596.17	3541.07
٧	Profit Before Exceptional And Extraordinary Items And Tax (III-IV)	268.80	169.60	260.16	429.76
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit Before Extraordinary Items And Tax (V-VI)	268.80	169.60	260.16	429.76
VIII	Extraordinary Items	0.00	0.00	0.00	0.00
IX	Profit Before Tax (VII-VIII)	268.80	169.60	260.16	429.76
X	Tax Expense				
	Current Tax	66.86	39.03	60.00	99.03
	Earliar Years Tax	0.00	1.15	0.00	1.15
	Deferred Tax	-5.14	21.88	-17.63	4.25
	Profit(Loss) For The Period From				
XI	Continuing Operations (IX-X)	196.80	151.31	182.53	333.84
XII	Profit (Loss) From Discontinuing Operations	0.00	0.00	0.00	0.00
XIII	Tax Expense Of Discontinuing Operations	0.00	0.00	0.00	0.00
XIV	Profit(Loss) From Discontinuing Operations After Tax (XII-XIII)	196.80	151.31	182.53	333.84
ΧV	Profit (Loss) For The Period	196.80	151.31	182.53	333.84
XVI	Earning Per Equity Share (Face Value of Rs . 10/-)				
	Basic (In Rs.)	2.33	1.72	2.24	3.96
	Diluted (In Rs.)	2.33	1.72	2.24	3.96

Date:-12th November 2025

Place:- Mumbai

Kashyap Pravi DIN: 01717036

Managing Director & Chairman

For And On Beh

#### **Amkay Products Limited** (Formerly Known as Amkay Products Private Limited)

Registered Office -: Bunglow No.68,Rashmi Park Chs Ltd, Dhumal Nagar Waliv Road, Tal-Vasai Dist-Thane Vasai Thane Maharashtra - 401208, CIN -: L51397MH2007PLC175403

**BALANCE SHEET AS AT 30th SEPTEMBER, 2025** 

(Rs In Lakhs) Sr. Particulars AS AT Note AS AT No 30-Sep-25 31-Mar-25 No. **Equity And Liabilities** Audited Audited Shareholders Funds a Share Capital 1 865.56 865.56 b Reserves And Surplus 2 1737.75 1540.95 2603.31 2406.51 Total (1) Share Application Money Pending Allotment Total (2) 0.00 0.00 Non-Current Liabilities Long Term Borrowings 104.72 3 79.82 Deferred Tax Liabilities (Net) 0.00 0.00 Other Long-Term Liabilities Long-Term Provisions 10.62 8.25 90.44 Total (3) 112.96 **Current Liabilities** Short-Term Borrowings 110.34 159.28 Trade Payables 5 (i) total outstanding dues of micro enterprises and small enterprises; and 205.61 179.45 (ii) total outstanding dues of creditors other than micro enterprises and small 60.82 82.95 enterprises. Other Current Liabilities 41.20 46.64 6 Short Term Provisions 7 24.15 0.88 442.12 Total (4) 469.20 Total Equity & Liabilities (1+2+3+4) 3135.87 2988.68 Assets Non-Current Assets Property Plant & Equipment & Intangible Assets 399.23 425,39 8 (i) Property Plant & Equipment 397.69 423.73 (ii) Intangible Assets 1.66 1.54 Non-Current Investments 9 626.78 684.92 Deferred Tax Assets (Net) 9A 20.44 25.58 Long-Term Loans And Advances 10 0.00 0.00 Other Non-Current Assets 11 142.69 136.22 1189.13 1272.11 Total (1) 2 **Current Assets** Current Investment 0.00 0.00 12 h Inventories 793.14 812.49 13 601.10 Trade Receivables 732.73 C 14 Cash And Cash Equivalents d 15 216.93 153.61 Short-Term Loans And Advances 16 189.15 143.58 Other Current Assets 17 14.78 5.78 1946.74 1716.57 Total (2) Total Assets (1+2) 3135.87 2988.68

Date:-12th November 2025

Place: Mumbai

Kashyap P. Mod Managing Director & Chair

DIN No: 01717036

For And On Behalf Of Boa **Amkay Products Li** 

## Amkay Products Limited (Formerly Known as Amkay Products Private Limited)

Registered Office - : Bunglow No.68,Rashmi Park Chs Ltd, Dhumal Nagar Waliv Road, Tal-Vasai Dist- Thane Vasai Thane Maharashtra - 401208, CIN - : L51397MH2007PLC175403

STATEMENT OF CASH FLOW FOR THE YEAR ENDED SEPTEMBER 30, 2025

(Amount in ₹ Lakhs)

	Particulars	For the period ended September 30, 2025	For the year ended March 31, 2025
A.	CASH FLOW FROM OPERATING ACTIVITIES		
	Net profit before tax	268.80	429.7
	Adjustments for:		
	Depreciation and amortisation expense	42.63	82.9
	(Profit) / Loss on sale of fixed assets	0.00	-2.9
	(Profit) / Loss on Sale of investments	-19.22	-103.3
	Interest and other income on investments	-12.64	-14.2
	Finance Cost	25.38	31.6
	Provision for Gratuity	2.62	1.6
	Bad debts written off	0.08	3.7
	Unrealised Foreign Exchange Gain/(Loss)	0.00	0.3
	Operating profit / (loss) before working capital changes	307.65	429.0
	Changes in working capital:		
	Increase / (Decrease) in trade payable	4.03	56.0
	Increase / (Decrease) in other current liabilities	-6.37	12.9
	Increase / (Decrease) in Short term provisions	0.00	0.0
	(Increase) / Decrease in inventories	19.35	-251.
	(Increase) / Decrease in trade receivables	-131.71	-206.0
	(Increase) / Decrease in trade receivables (Increase) / Decrease in short term loan and advances	-45.57	33.4
		-9.00	-4.1
	(Increase) / Decrease in Other Current Assets	-169.28	-359.
	A COLUMN THE COLUMN TH	138.38	70.
	CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	-42.90	-102.
	Less: Income Taxes paid		
	NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	95.48	-31.
В.	CASH FLOW FROM INVESTING ACTIVITIES		0.47
	Purchase of tangible / intangible assets net of Subsidy Received	-16.47	-247.5
	(Increase) / Decrease in long term loan and advances	0.00	0.
	(Increase) / Decrease in non current Assets	-6.46	-25.
	(Profit)/Loss on sale of investments	19.22	103.
	Investment in Mutual Fund	58.14	-428.
	Interest and other income on investments	12.64	14.
	NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES	67.07	-583.
C.	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from Issue of Share Capital	0.00	1260.
	Payment of IPO related Expenses	0.00	-188.
	Finance Cost	-25.38	-31.
	Increase/(Decrease) in Short-term Borrowing	-48.94	-259.
	Increase/(Decrease) in Long-term Borrowing	-24.90	-22.
	Increase/(Decrease) in Other Long Term Liabilities	0.00	0.
	NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES	-99.22	758.
	NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS		
	(A+B+C)	63.32	142.
	Cash and Cash equivalents at beginning period		
	Cash and Cash equivalents at beginning period	153.61	10.
	Cash and Cash equivalents at end of period	216.93	153.
ο.	Cash and Cash equivalents comprise of		
	Cash on hand	6.61	5.
	Balances with banks		
	In current accounts	-4.68	12.
	Other Balances (As per AS - 3)	215.00	135.
	Total	216.93	153.

This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised) "Cash Flow Statements"

Date:-12th November 2025 Place:- Mumbai

Managing Directo

#### Notes on Financial Result for the Half year ended 30th September, 2025:-

- 1 The above result have been reviewed by the Audit Committee and have been approved by the Board of Directors of the company at their respective meetings held on 12th November, 2025.
- The results for the half year ended 30th September, 2025 has been reviewed by the statutory auditor of the company in compliance with regulation 33 of SEBI(listing obligations and disclosure requirements) regulation, 2015.
- The figure for the half year ended March 31 2025, as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the Unaudited figures for the period April 1, 2024 to September 30, 2024 as certified by the management.
- As per Accounting standard 17 on "segment Reporting" (AS-17), the company has only one reportable segment viz Healthcare Devices and consumable and product, therefore segment disclosure is not applicable.
- As per MCA notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulation 2018 are exeputed from complusory requirement of adoption of IND-AS.
- Earning Per Share are calculated on weighted avergae of the Share Capital Outstanding during the year/half year/ period EPS is not annualised (As-20)
- The balance of Trade Payables, Trade Receivables, Loans and Advances, Deposits, Current Liabilities etc. are considered as per books of account, pending confirmations and reconciliation. In the Opinion of the management, since the amount due to/ from these parties are fully payable/recoverable, no material difference is expected to arise at the time of settlement, requiring accounting effect as on 30-09-2025 except otherwise stated.
- 8 Previous year's/ period's figure have been regrouped/rearrnaged wherever necessary.

For And On Behalf Of Board,

Amkay Productimites

Date:-12th November 2025

Place:- Mumbai

DIN No: 01717036

Managing Director & Chairman

# R K Jagetiya & Co

CAR


Chartered Accountants

B-303, Eklavya CHSL,
N. L. Complex, Dahisar East,
Mumbai – 400068
Mobile+91 9820800926
E-mail: rkjagetiyaco@gmail.com

Limited Review Report on the Unaudited Financial Results for the Half year ended on 30<sup>th</sup> September 2025 of the Amkay Products Limited under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Amkay Products Limited

- We have reviewed the accompanying statement of unaudited financial results
  of Amkay Products Limited ("the Company") for the half year ended 30
  September 2025 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ('AS-25'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations'). Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Corporation personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in



accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R K Jagetiya & Co

JAGETIYA

FRN 146264W

Chartered Accountants

FRN 146264W

(Ravi K Jagetiya)

Proprietor

Membership No. 134691 Date: 12<sup>th</sup> November, 2025

Place: Mumbai

UDIN: 25134691BMGTNW4742



CE ISO 9001:2015

# AMKAY PRODUCTS LIMITED

### Mfg.of Medical Devices & Disposables

Regd. Office: Amkay Enclave, 68, Rashmi Park Bungalow, Dhumaal Nagar, Waliv Road, Vasai (East), Palghar - 401208, Maharashtra, India.

Email: info@amkayproducts.com Website: www.amkayproducts.com

Phone: 91520 94440 CIN: U51397MH2007PLC175403

Date: 12th November, 2025

To, The Manager Listing Department BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai-400001

Scrip Code: 544169

# Sub.: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations an Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 read with SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016; we hereby declared that the Statutory Auditors of the Company M/s. R K Jagetiya & Co., Chartered Accountants, Mumbai (Firm Registration No. 146264W) have issued the Limited Review Reports with Unmodified Opinion in respect of the Unaudited Financial Results for the half year ended on September 30, 2025.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For Amkay Products Limited

Kashyap Pravin Mody Managing Director DIN: 01717036

Your Partner in Healthcare